PharmaEngine (ROCO:4162) Scaled Net Operating Assets: 0.05 (As of Dec. 2025)


ROCO:4162 PharmaEngine Inc ROCO:4162
78 GF Score
Price NT$63.80
GF Value NT$115.25
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is PharmaEngine Scaled Net Operating Assets?

PharmaEngine ROCO:4162 +0.31% 78 Scaled Net Operating Assets is 0.05 as of Dec. 2025. GuruFocus rates ROCO:4162 with a GF Score™ of 78/100 and a GF Value™ of NT$115.25 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

PharmaEngine's operating assets for the quarter that ended in Dec. 2025 was NT$430.7 Mil. PharmaEngine's operating liabilities for the quarter that ended in Dec. 2025 was NT$179.5 Mil. PharmaEngine's Total Assets for the quarter that ended in Sep. 2025 was NT$4,907.7 Mil. Therefore, PharmaEngine's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was 0.05.

PharmaEngine Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for PharmaEngine's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaEngine Scaled Net Operating Assets Chart

PharmaEngine Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.06 0.06 0.39 0.04

PharmaEngine Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 -0.03 -0.12 0.04 0.05

ROCO:4162 vs VRTX, REGN, ALNY: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, PharmaEngine's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmaEngine Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaEngine's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where PharmaEngine's Scaled Net Operating Assets falls into.


ROCO:4162
78GF Score
PharmaEngine Inc ROCO:4162
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaEngine Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

PharmaEngine's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(430.692-179.47)/5847.811
=0.04

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=5147.512 - 4716.82
=430.692

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=221.594 - 33.46 - 8.664
=179.47

PharmaEngine's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2025 )
=(Operating Assets (Q: Dec. 2025 )-Operating Liabilities (Q: Dec. 2025 ))/Total Assets (Q: Sep. 2025 )
=(430.692-179.47)/4907.683
=0.05

where

Operating Assets(Q: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=5147.512 - 4716.82
=430.692

Operating Liabilities(Q: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=221.594 - 33.46 - 8.664
=179.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.05 mean?
PharmaEngine (ROCO:4162) has a Scaled Net Operating Assets of 0.05 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on PharmaEngine and its competitors.
Is PharmaEngine's Scaled Net Operating Assets too high?
PharmaEngine's current Scaled Net Operating Assets is 0.05. Overall, PharmaEngine has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PharmaEngine's Scaled Net Operating Assets compare to VRTX and REGN?
PharmaEngine's Scaled Net Operating Assets of 0.05 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on PharmaEngine and its competitors. PharmaEngine's current Scaled Net Operating Assets is 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaEngine stock overvalued right now?
Based on GuruFocus' analysis, PharmaEngine (ROCO:4162) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$115.25, compared to a current price of NT$63.80 — trading 44.6% below its estimated fair value. The current Scaled Net Operating Assets is 0.05. PharmaEngine's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For PharmaEngine (ROCO:4162), the current Scaled Net Operating Assets is 0.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PharmaEngine (ROCO:4162) Overvalued in 2026?

Based on GuruFocus' analysis, PharmaEngine stock appears to be undervalued. The current stock price of NT$63.80 is trading 44.6% below its estimated GF Value™ of NT$115.25. GuruFocus considers PharmaEngine to be Significantly Undervalued.

Key valuation signals for ROCO:4162:

  • Scaled Net Operating Assets: 0.05
  • GF Value™: NT$115.25 vs. price of NT$63.80 (44.6% below fair value)
  • GF Score™: 78/100 with 3 warning signs

No single metric tells the full story. See the ROCO:4162 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PharmaEngine Business Description

Address No. 10, Minsheng East Road, 11th Floor, Section 3, Taipei, TWN, 104
PharmaEngine Inc is a biopharmaceutical company engaged in the development of new drugs and therapeutic drugs for cancer. It is a specialty pharma company that adopts the no research, development-only model and the networked pharma model for new drug development. Its key products and pipeline projects include ONIVYDE, a treatment for metastatic pancreatic cancer approved in multiple markets, as well as oncology candidates such as PEP07 and PEP08. It generates revenue from the sales of goods.
78GF Score

Get the complete analysis for ROCO:4162

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$63.80
Price
NT$115.25
GF Value